Maria G. Castro

Q: What Schools Are Affiliated With Maria G. Castro

Maria G. Castro is affiliated with the following schools: National University of La Plata, Vrije Universiteit Amsterdam, University of Michigan, University of Buenos Aires, University of California, Los Angeles, Stanford University, University of Manchester

Maria G. Castro's AcademicInfluence.com Rankings

Maria G. Castro

Biology

#5724

World Rank

#8271

Historical Rank

Neuroscience

#1729

World Rank

#1783

Historical Rank

biology Degrees

Download Badge

Biology

Maria G. Castro's Degrees

Bachelors Neuroscience University of Buenos Aires

Why Is Maria G. Castro Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Maria G. Castro is the R. C. Schneider Collegiate Professor of Neurosurgery and a Professor of Cell and Developmental Biology at the University of Michigan Medical School. Her research focuses on cancer immunology and gliomas.

(See a Problem?)

Maria G. Castro's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Consensus guidelines for the detection of immunogenic cell death (2014) (634)
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression (2009) (328)
Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials (1999) (317)
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression (2007) (310)
Platelets mediate cytotoxic T lymphocyte–induced liver damage (2005) (273)
Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. (2000) (257)
Regulatable gene expression systems for gene therapy applications: progress and future challenges. (2005) (246)
Post-translational processing of proopiomelanocortin in the pituitary and in the brain. (1997) (217)
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma (2016) (198)
Current and future strategies for the treatment of malignant brain tumors. (2003) (180)
Progress in gene therapy for neurological disorders (2013) (172)
Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. (2001) (167)
Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. (2005) (156)
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. (2007) (155)
Molecular indetermination in the transition to error catastrophe: Systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity (2002) (145)
Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination (2001) (143)
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response (2019) (142)
Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials (2008) (137)
Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy12 (2014) (136)
High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme. (2019) (128)
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. (2005) (127)
Interleukin-1 Mediates a Rapid Inflammatory Response After Injection of Adenoviral Vectors into the Brain (1999) (125)
Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. (2017) (120)
Biosynthesis of corticotropin-releasing hormone in human T-lymphocytes (1993) (116)
Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. (2001) (112)
Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. (2000) (108)
Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. (1999) (108)
In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain (2006) (105)
Gene therapy and targeted toxins for glioma. (2005) (103)
Prolonged Blockade of CD40-CD40 Ligand Interactions by Gene Transfer of CD40Ig Results in Long-Term Heart Allograft Survival and Donor-Specific Hyporesponsiveness, But Does Not Prevent Chronic Rejection1 (2002) (98)
Tolerance to Cardiac Allografts Via Local and Systemic Mechanisms After Adenovirus-Mediated CTLA4Ig Expression1 (2000) (96)
Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity (2009) (95)
Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy (2019) (95)
Performance of CMS muon reconstruction in cosmic-ray events (2010) (93)
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics (2010) (92)
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. (2004) (88)
Viral vectors for gene delivery and gene therapy within the endocrine system. (2000) (87)
Performance and Operation of the CMS Electromagnetic Calorimeter (2010) (86)
Regulatable Gutless Adenovirus Vectors Sustain Inducible Transgene Expression in the Brain in the Presence of an Immune Response against Adenoviruses (2006) (84)
One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. (2007) (83)
Fms-Like Tyrosine Kinase 3 Ligand Recruits Plasmacytoid Dendritic Cells to the Brain1 (2006) (83)
Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. (1999) (83)
Adenovirus-Mediated Gene Transfer of a Secreted Transforming Growth Factor-&bgr; Type II Receptor Inhibits Luminal Loss and Constrictive Remodeling After Coronary Angioplasty and Enhances Adventitial Collagen Deposition (2001) (82)
Replicative retroviral vectors for cancer gene therapy (2003) (82)
Cell-type-specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression. (2000) (82)
Mutant ATRX: uncovering a new therapeutic target for glioma (2018) (81)
Engineering patient-specific cancer immunotherapies (2019) (81)
Identification and Filtering of Uncharacteristic Noise in the CMS Hadron Calorimeter (2010) (80)
The regulation of the corticomelanotropic cell activity in Aves--II. Effect of various peptides on the release of ACTH from dispersed, perfused duck pituitary cells. (1986) (79)
B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. (2011) (78)
Alignment of the CMS silicon tracker during commissioning with cosmic rays (2010) (78)
Purine metabolism regulates DNA repair and therapy resistance in glioblastoma (2020) (77)
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. (2007) (74)
Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences (2003) (73)
Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model (2004) (72)
Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. (1997) (70)
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. (2008) (69)
Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression (2009) (68)
CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study (2016) (68)
Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? (2009) (65)
Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. (2014) (63)
Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. (2010) (61)
Recent advances and future of immunotherapy for glioblastoma (2016) (61)
Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene. (2010) (60)
Transcriptional Targeting to Anterior Pituitary Lactotrophic Cells Using Recombinant Adenovirus Vectors in Vitro and in Vivo in Normal and Estrogen/Sulpiride-Induced Hyperplasic Anterior Pituitaries. (2000) (59)
Gene therapy for brain tumors: Basic developments and clinical implementation (2012) (58)
Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas. (2000) (57)
Current state and future prospects of immunotherapy for glioma. (2018) (56)
Adenovector GAD65 gene delivery into the rat trigeminal ganglion produces orofacial analgesia (2009) (55)
Platelets Mediate Cytotoxic T Lymphocyte-Induced Liver Damage. (2005) (54)
Cytotoxic immunological synapses do not restrict the action of interferon-γ to antigenic target cells (2012) (52)
Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. (2005) (52)
Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: long term expression, cell cycle dependency, and effects on hormone secretion. (1997) (51)
Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma (2016) (51)
Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. (2006) (50)
T Cells' Immunological Synapses Induce Polarization of Brain Astrocytes In Vivo and In Vitro: A Novel Astrocyte Response Mechanism to Cellular Injury (2008) (50)
Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. (2009) (50)
Gene Transfer into Neural Cells In Vitro Using Adenoviral Vectors (2000) (50)
Adenovirus Binding to the Coxsackievirus and Adenovirus Receptor or Integrins Is Not Required To Elicit Brain Inflammation but Is Necessary To Transduce Specific Neural Cell Types (2002) (49)
Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK (2000) (49)
Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. (2009) (48)
Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. (2010) (48)
Direct regulation of GnRH transcription by CRF‐like peptides in an immortalized neuronal cell line (1998) (47)
Alignment of the CMS muon system with cosmic-ray and beam-halo muons (2010) (47)
Overview of current immunotherapeutic strategies for glioma. (2015) (46)
Adenoviral vector-mediated gene therapy for gliomas: coming of age (2014) (46)
Different tropism of adenoviruses and adeno-associated viruses to corneal cells: implications for corneal gene therapy (2008) (45)
Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism (2016) (45)
Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Antiglioma Cytotoxic and Memory T-Cell Functions (2014) (45)
Performance of the CMS drift-tube chamber local trigger with cosmic rays (2010) (44)
Commissioning and performance of the CMS pixel tracker with cosmic ray muons (2010) (44)
Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes. (2005) (44)
Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. (2007) (43)
Precise Mapping of the Magnetic Field in the CMS Barrel Yoke using Cosmic Rays (2010) (42)
Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. (2017) (42)
Current Approaches for Glioma Gene Therapy and Virotherapy (2021) (41)
ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability (2016) (41)
Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig. (2003) (41)
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas (2020) (41)
Inhibition of 2-Hydroxyglutarate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity in Mice. (2020) (40)
Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. (2006) (39)
Performance of the CMS hadron calorimeter with cosmic ray muons and LHC beam data (2010) (39)
Use of recombinant vectors derived from herpes simplex virus 1 mutant tsK for short-term expression of transgenes encoding cytoplasmic and membrane anchored proteins in postmitotic polarized cortical neurons and glial cells in vitro (1994) (39)
Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. (2012) (39)
Adenovirus-Mediated Gene Transfer of Transforming Growth Factor-&bgr;3, but Not Transforming Growth Factor-&bgr;1, Inhibits Constrictive Remodeling and Reduces Luminal Loss After Coronary Angioplasty (2003) (37)
Engineering the Brain Tumor Microenvironment Enhances the Efficacy of Dendritic Cell Vaccination: Implications for Clinical Trial Design (2011) (37)
Progesterone antagonizes the permissive action of estradiol on tumor necrosis factor-alpha-induced apoptosis of anterior pituitary cells. (2005) (37)
In Vivo Polarization of IFN-γ at Kupfer and Non-Kupfer Immunological Synapses during the Clearance of Virally Infected Brain Cells12 (2008) (37)
Development of a Novel Helper-Dependent Adenovirus-Epstein-Barr Virus Hybrid System for the Stable Transformation of Mammalian Cells (2004) (37)
Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU (2001) (36)
Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. (2001) (36)
Performance study of the CMS barrel resistive plate chambers with cosmic rays (2010) (36)
A Novel Bicistronic High-Capacity Gutless Adenovirus Vector That Drives Constitutive Expression of Herpes Simplex Virus Type 1 Thymidine Kinase and Tet-Inducible Expression of Flt3L for Glioma Therapeutics (2010) (36)
Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy (2019) (36)
Performance of the CMS Drift Tube Chambers with Cosmic Rays (2010) (36)
Estrogens sensitize anterior pituitary gland to apoptosis. (2004) (36)
Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. (2016) (35)
Gene therapy and targeted toxins for glioma : Gene therapy for cancer (2005) (35)
Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. (2008) (35)
Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy (2018) (34)
Study of the Efficacy, Biodistribution, and Safety Profile of Therapeutic Gutless Adenovirus Vectors as a Prelude to a Phase I Clinical Trial for Glioblastoma (2010) (34)
Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF-κB Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model (2012) (33)
Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. (2006) (33)
CMS Data Processing Workflows during an Extended Cosmic Ray Run (2010) (33)
Preclinical Characterization of Signal Transducer and Activator of Transcription 3 Small Molecule Inhibitors for Primary and Metastatic Brain Cancer Therapy (2014) (33)
Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma. (2015) (33)
Switching on and off transgene expression within lactotrophic cells in the anterior pituitary gland in vivo. (2001) (32)
Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS. (2001) (32)
Performance of CMS Hadron Calorimeter Timing and Synchronization using Test Beam, Cosmic Ray, and LHC Beam Data. (2010) (31)
Progress in gene therapy for neurological disorders (2013) (31)
Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age (2005) (30)
Melanoma induced immunosuppression is mediated by hematopoietic dysregulation (2018) (30)
G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy (2021) (30)
Human Flt3L Generates Dendritic Cells from Canine Peripheral Blood Precursors: Implications for a Dog Glioma Clinical Trial (2010) (30)
Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models (2014) (30)
High-capacity, helper-dependent, "gutless" adenoviral vectors for gene transfer into brain. (2002) (30)
Real-time imaging of gene promoter activity using an adenoviral reporter construct demonstrates transcriptional dynamics in normal anterior pituitary cells. (2003) (29)
High-Capacity Adenovirus Vector-Mediated Anti-Glioma Gene Therapy in the Presence of Systemic Antiadenovirus Immunity (2008) (29)
Efficacy of nonviral gene transfer in the canine brain. (2007) (29)
Long-term transgene expression within the anterior pituitary gland in situ: impact on circulating hormone levels, cellular and antibody-mediated immune responses. (2001) (29)
Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. (2008) (29)
Natural killer cells require monocytic Gr-1+/CD11b+ myeloid cells to eradicate orthotopically engrafted glioma cells (2016) (29)
Performance of the CMS cathode strip chambers with cosmic rays (2010) (29)
Processing of procorticotropin-releasing hormone (pro-CRH): molecular forms of CRH in normal and preeclamptic pregnancy. (2000) (28)
Gene therapy strategies for the treatment of pituitary tumours. (1999) (28)
Combined Flt3L/TK Gene Therapy Induces Immunological Surveillance Which Mediates an Immune Response Against a Surrogate Brain Tumor Neoantigen. (2011) (28)
Turning the gene tap off; implications of regulating gene expression for cancer therapeutics (2008) (28)
Calibration of the CMS drift tube chambers and measurement of the drift velocity with cosmic rays (2010) (27)
Adenovirus-driven overexpression of proteinases in organ-cultured normal human corneas leads to diabetic-like changes (2010) (27)
Fine synchronization of the CMS muon drift-tube local trigger using cosmic rays (2010) (27)
Photoperiodic regulation of prolactin gene expression in the Syrian hamster by a pars tuberalis-derived factor. (2001) (26)
Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. (2013) (26)
A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transfer (2003) (26)
Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries. (2000) (26)
FYN tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates anti-glioma immune responses (2019) (26)
Gene Transfer into Rat Brain Using Adenoviral Vectors (2000) (25)
Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. (2017) (25)
Progress and challenges in viral vector-mediated gene transfer to the brain. (2002) (25)
Cell type-specific adenoviral transgene expression in the intact ovine pituitary gland after stereotaxic delivery: an in vivo system for long-term multiple parameter evaluation of human pituitary gene therapy. (2001) (24)
Adenovirus vector–mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane (2002) (24)
Rapid Upregulation of Interferon-Regulated and Chemokine mRNAs upon Injection of 108 International Units, but Not Lower Doses, of Adenoviral Vectors into the Brain (2006) (24)
Use of recombinant herpes simplex virus type 1 vectors for gene transfer into tumour and normal anterior pituitary cells (1998) (24)
Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier! (2014) (24)
Commissioning of the CMS High-Level Trigger with Cosmic Rays (2010) (24)
Gene Transfer into Neural Cells In Vitro Using Adenoviral Vectors (2000) (23)
Transmembrane signals mediating adrenocorticotropin release from mouse anterior pituitary cells (1989) (23)
Genetic engineering within the adult brain: Implications for molecular approaches to behavioral neuroscience (2001) (22)
Studies on the prolactin-releasing mechanism of histones H2A and H2B. (2000) (22)
Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS. (2009) (22)
CD20, CD3, and CD40 Ligand Microclusters Segregate Three-Dimensionally In Vivo at B-Cell-T-Cell Immunological Synapses after Viral Immunity in Primate Brain (2008) (22)
A platform for artificial intelligence based identification of the extravasation potential of cancer cells into the brain metastatic niche. (2019) (21)
Procorticotrophin-releasing hormone: endoproteolytic processing and differential release of its derived peptides within AtT20 cells (1998) (21)
Herpes simplex virus 1 (HSV-1) helper co-infection affects the distribution of an amplicon encoded protein in glia. (1994) (21)
Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cells. (2012) (21)
Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma (2020) (21)
Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas (2020) (20)
Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments (2021) (20)
Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. (2012) (20)
Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology (2010) (20)
Diminished diurnal secretion of corticosterone in aging female but not male rats. (1989) (20)
Effect of the corticotrophin releasing hormone precursor on interleukin-6 release by human mononuclear cells. (1997) (19)
First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system. (2019) (19)
Gene therapy for liver transplantation using adenoviral vectors: CD40-CD154 blockade by gene transfer of CD40Ig protects rat livers from cold ischemia and reperfusion injury. (2004) (19)
Cell-type specific expression in the pituitary: physiology and gene therapy. (1999) (19)
Matrix Metalloproteinase Activity in Infections by an Encephalitic Virus, Mouse Adenovirus Type 1 (2017) (19)
ADENOVIRAL‐MEDIATED GENE TRANSFERINTO THE CANINE BRAIN IN VIVO (2007) (18)
Immunology of neurological gene therapy: How T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses (2007) (18)
Presence of pro-vasopressin mRNA, neurophysin and arginine vasopressin in mouse anterior pituitary cells and the AtT-20 corticotrophic tumour cell line. (1988) (18)
Dendritic Cell-Based Immunotherapy for Glioma: Multiple Regimens and Implications in Clinical Trials (2013) (18)
Assessing the Role of STAT3 in DC Differentiation and Autologous DC Immunotherapy in Mouse Models of GBM (2014) (18)
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. (2015) (17)
Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event (2017) (17)
Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty. (2003) (16)
Recent advances in the pharmacology of neurological gene therapy. (2004) (16)
Prohormone and proneuropeptide synthesis and secretion. (1997) (16)
Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. (2011) (16)
Biosynthesis of corticotrophin-releasing hormone (CRH) in mouse corticotrophic tumour cells expressing the human proCRH gene: intracellular storage and regulated secretion. (1991) (16)
Immunoreactive delta sleep-inducing peptide secretion from mouse dissociated, anterior pituitary cells: regulation by corticotropin-releasing factor and arginine vasopressin. (1989) (16)
Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells (2001) (16)
An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines. (1999) (15)
Human gene therapy and imaging in neurological diseases (2005) (15)
Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells (2021) (15)
Microtubule targeting agents in glioma. (2016) (15)
Lack of Humoral Immune Response to the Tetracycline (Tet) Activator in Rats Injected Intracranially with Tet-off rAAV Vectors (2010) (15)
Adenoviruses Encoding HPRT Correct Biochemical Abnormalities of HPRT-Deficient Cells and Allow Their Survival in Negative Selection Medium (2004) (15)
Pro-opiomelanocortin and pro-vasopressin converting enzyme in pituitary secretory vesicles. (1988) (15)
Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. (2011) (15)
Regulatable and cell-type specific transgene expression in glial cells: prospects for gene therapy for neurological disorders. (2001) (15)
Expression of Biologically Active Procorticotrophin‐Releasing Hormone (proCRH) in Stably Transfected CHO‐K1 Cells: Characterization of Nuclear proCRH (1995) (15)
Single vs. combination immunotherapeutic strategies for glioma (2017) (15)
Adenovirus-mediated gene transfer in the ovine pituitary gland is associated with hypophysitis. (2002) (15)
Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma (2020) (15)
Reversibility of glioma stem cells’ phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery tool (2016) (15)
Prospects of biological and synthetic pharmacotherapies for glioblastoma (2020) (14)
Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer (2017) (14)
The use of inclusion bodies, isolated from Escherichia coli expressing corticotrophin-releasing hormone precursor, to raise specific antibodies against the neuropeptide moiety. (1990) (13)
Molecular therapy in a model neuroendocrine disease: developing clinical gene therapy for pituitary tumours (2001) (13)
Adenoviral vectors encoding tumor necrosis factor-alpha and FasL induce apoptosis of normal and tumoral anterior pituitary cells. (2006) (13)
Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications (2021) (13)
Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy. (2022) (13)
Gene therapy and targeted toxins for glioma. (2005) (13)
Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease. (2019) (12)
Effects of corticotrophin-releasing factor and arginine-vasopressin on proopiomelanocortin (POMC) mRNA levels, release and storage of adrenocorticotrophin from mouse anterior pituitary cells. (1993) (12)
Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral Deficits. (2008) (12)
Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders. (2003) (12)
Transgenic Models in Endocrinology (2001) (12)
Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities (2020) (12)
Subcellular post-transcriptional targeting: delivery of an intracellular protein to the extracellular leaflet of the plasma membrane using a glycosyl-phosphatidyl inositol (GPI) membrane anchor in neurons and polarised epithelial cells (2000) (12)
Expression and partial purification of human prolactin in Escherichia coli. (1991) (12)
Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma. (2013) (11)
The regulation of the corticomelanotropic cell activity in aves. III--Effect of various peptides on the release of MSH from dispersed, perfused duck pituitary cells. Cosecretion of ACTH with MSH. (1988) (11)
Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis (2020) (11)
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development (2020) (11)
Neuro-oncology: The long and winding road—gene therapy for glioma (2013) (11)
Expression of prolactin receptors and regulation of cell proliferation by prolactin, corticotropin-releasing factor, and corticosterone in a neuroblastoma cell line. (2002) (11)
Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors. (2006) (11)
Gene therapy for pituitary tumors. (2005) (11)
Synaptogenesis and distribution of presynaptic axonal varicosities in low density primary cultures of neocortex: an immunocytochemical study utilizing synaptic vesicle-specific antibodies, and an electrophysiological examination utilizing whole cell recording (1995) (11)
HMGB1 Mediates Endogenous TLR2 Activation And Brain Tumor Regression. (2008) (10)
Procorticotrophin releasing hormone is endoproteolytically processed by the prohormone convertase PC2 but not by PC1 within stably transfected CHO-K1 cells. (1996) (10)
Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression (2022) (10)
Simultaneous detection of amplicon and HSV-1 helper encoded proteins reveals that neurons and astrocytoma cells do express amplicon-borne transgenes in the absence of synthesis of virus immediate early proteins. (1995) (10)
The regulation of the cortico-melanotrophic cell activity in aves—I. Evaluation and selection of in vitro systems for testing ACTH-releasing substances in the duck pituitary (1984) (10)
Differential Effect of Aging on Serum Levels of Prolactin and α-Melanotropin in Rats (1991) (10)
Lentiviral-Induced High-Grade Gliomas in Rats: The Effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H (2014) (10)
Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression. (2003) (10)
Marmosets as a preclinical model for testing “off-label” use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors (2014) (9)
Gene therapy strategies for intracranial tumours: glioma and pituitary adenomas. (2000) (9)
Gene therapy for inherited neurological disorders: towards therapeutic intervention in the Lesch-Nyhan syndrome. (1998) (9)
Expression of biologically active human pre-procorticotropin releasing hormone in E. coli: characterization and purification. (1990) (9)
Gene therapy for pituitary tumors: from preclinical models to clinical implementation (2003) (9)
IDH 1R 132 H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response (9)
Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators. (2008) (9)
Thymosin peptides stimulate corticotropin release by a calcium-dependent mechanism. (1993) (9)
Thymus-pituitary interactions during ageing. (1993) (9)
Generation of a Recombinant Herpes Simplex Virus Type 1 Expressing the Rat Corticotropin- Releasing Hormone Precursor: Endoproteolytic Processing, Intracellular Targeting and Biological Activity (1999) (9)
Adenovirus-mediated CD40Ig expression attenuates chronic vascular rejection lesions in an aorta allotransplantation model. (2002) (9)
Histones and related preparations interfere with immunoassays for peptide hormones (1993) (8)
Herpes simplex virus temperature-sensitive mutant tsK as a vector for neuronal gene transfer (1995) (8)
Electrophysiological evidence against a neurotransmitter role of corticotropin-releasing hormone (CRH) in primary somatosensory cortex (1998) (8)
Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. (2016) (8)
Intrapituitary adenoviral administration of 7B2 can extend life span and reverse endocrinological deficiencies in 7B2 null mice. (2002) (8)
Recent developments in gene therapy: applications for the treatment of pituitary tumours. (1999) (8)
Targeting gliomas with STAT3-silencing nanoparticles (2021) (8)
IDH1R132H acts as a tumor suppressor in glioma via epigenetic upregulation of the DNA damage response (2018) (8)
The basic science of brain-tumour gene therapy. (1999) (8)
Adenovirus‐mediated gene transfer to human lens epithelial cells in organ culture (2000) (8)
Cell Type-Specific Adenoviral Transgene Expression in the Intact Ovine Pituitary Gland after Stereotaxic Delivery: An in VivoSystem for Long-Term Multiple Parameter Evaluation of Human Pituitary Gene Therapy**This work was supported by the Medical Research Council, the Biotechnology and Biological S (2001) (7)
Rodent Glioma Models: Intracranial Stereotactic Allografts and Xenografts. (2012) (7)
Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion. (2020) (7)
Cell type-specific expression from viral promoters within replication-deficient adenovirus recombinants in primary neocortical cultures. (1995) (7)
Chapter 2 – Non-neurotropic adenovirus: A vector for gene transfer to the brain and possible gene therapy of neurological disorders (1995) (7)
Gene therapy for Parkinson's disease: recent achievements and remaining challenges. (2001) (7)
Tumor Mutational Burden Predicts Survival In Patients With Low Grade Gliomas Expressing Mutated IDH1 (2020) (7)
Use of recombinant adenovirus for gene transfer into the rat brain. Evaluation of gene transfer efficiency, toxicity, and inflammatory and immune reactions. (2003) (7)
On the stimulatory nature of the control of MSH secretion in ducks. (1986) (6)
Gene therapy for pituitary tumours. (1999) (6)
In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system. (2005) (6)
Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy (2014) (6)
Virus Vectors for use in the Central Nervous System (2003) (6)
A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1 (2021) (6)
Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab (2018) (6)
Nuclear translocation of neuropeptides: possible nuclear roles. (1995) (6)
The value of EGFRvIII as the target for glioma vaccines. (2014) (6)
Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1 (2020) (6)
Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model. (2016) (6)
Isolation and characterization of immune cells from the tumor microenvironment of genetically engineered pediatric high-grade glioma models using the sleeping beauty transposon system. (2020) (6)
Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials. (2009) (6)
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies (2021) (5)
T lymphocytes as dynamic regulators of glioma pathobiology. (2022) (5)
Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models. (2020) (5)
Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography. (2020) (5)
There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. (2014) (5)
Novel Gene Therapeutic Approaches to Brain Cancer (2006) (5)
Erratum: Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain (Journal of Neuroscience (February 15, 1999) (1517-1523)) (1999) (4)
Erratum: Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses. (2020) (4)
An Optimized Protocol for In Vivo Analysis of Tumor Cell Division in a Sleeping Beauty-Mediated Mouse Glioma Model (2020) (4)
HSV1 vectors to study protein targeting in neurones: are glycosyl-phosphatidylinositol anchors polarized targeting signals in neurones? (1994) (4)
Pushing the limits of glioma resection using electrophysiologic brain mapping. (2012) (4)
Gene therapy in the central nervous system (2005) (4)
Post-translational processing and regulated release of corticotropin-releasing hormone (CRH) in AtT20 cells expressing the human proCRH gene. (1991) (4)
ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM (2019) (4)
Enhances Adventitial Collagen Deposition Receptor Inhibits Luminal Loss and Constrictive Remodeling After Coronary Angioplasty Type II β Adenovirus-Mediated Gene Transfer of a Secreted Transforming Growth Factor (2001) (4)
Generation and characterization of an antiserum reactive with a proteolytic processing site within rat procorticotrophin-releasing hormone (1995) (4)
PROBING THE QUARK-GLUON PLASMA AT THE LHC WITH Z0-TAGGED JETS IN CMS (2007) (4)
Adenovirus vectors to transfer genes into neurones: implications for gene therapy of neurological disorders. (1994) (4)
Erratum: Human gene therapy and imaging in neurological diseases (European Journal of Nuclear Medicine and Molecular Imaging (2005) 32 Suppl 2 (S358-S383) DOI: 10.1007/s00259-005-1960-3) (2006) (4)
Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment (2022) (4)
Performance of the CMS Level-1 Trigger during Commissioning with Cosmic Ray Muons (2010) (3)
Human gene therapy and imaging in neurological diseases (2005) (3)
Differential effect of aging on serum levels of prolactin and alpha-melanotropin in rats. (1991) (3)
Gene therapy continues to make progress: clinical and regulatory perspectives. (2009) (3)
3131 ONCOSTREAMS: NOVEL DYNAMICS PATHOLOGICAL MULTICELLULAR STRUCTURES INVOLVED IN GLIOBLATOMA GROWTH AND INVASION (2019) (3)
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models (2022) (3)
Polarity development and synaptogenesis in low density primary cultures of neocortex. Use of herpes simplex virus-1 vectors to transfer genes into postmitotic neurons. (1993) (3)
Neocortical neuronal polarity: targeting of a foreign protein linked to a glycosyl-phosphatidylinositol (GPI) anchor in postmitotic neurons and polarized distribution of a marker of the trans-Golgi network (TGN 38). (1993) (3)
Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres. (2018) (3)
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures. (2019) (3)
Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas (2016) (3)
Identification and Visualization of CD8+ T Cell Mediated IFN-γ Signaling in Target Cells during an Antiviral Immune Response in the Brain (2011) (3)
Genetically Engineered Mouse Model of Brainstem High-Grade Glioma (2020) (3)
Adenoviruses encoding HPRT correct the biochemical abnormalities fully only in HPRT-deficient human cell lines: importance of species differences. (2000) (3)
G-CSF Secreted by Epigenetically Reprogrammed Mutant IDH1 Glioma Stem Cells Reverses the Myeloid Cells’-Mediated Immunosuppressive Tumor Microenvironment (2020) (3)
CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway (2021) (3)
The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications (2022) (3)
Gene therapy for the treatment of pituitary tumors (2009) (3)
Erratum: Progress in gene therapy for neurological disorders (Nature Reviews Neurology (2013) 9 (277-291) DOI: 10.1038/nrneurol.2013.56) (2013) (3)
Dilepton-tagged jets in heavy-ion collisions at the LHC (2010) (2)
Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma (2022) (2)
Calcium-phosphate, DEAE-dextran co-precipitation, and electroporation to transfer genes into neuronal and glial cell lines (1995) (2)
Transcriptional targeting to anterior pituitary lactotrophic cells using recombitant adenovirus vectors in vitro and in vivo (2000) (2)
Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity (2020) (2)
Herpes Simplex Virus Type 1 Thymidine Kinase Sequence Fused to the lacZ Gene Increases Levels of β-Galactosidase Activity per Genome of High-Capacity but Not First-Generation Adenoviral Vectors In Vitro and In Vivo (2008) (2)
IDH-Tau-EGFR triad defines the neovascular landscape of diffuse gliomas by controlling mesenchymal differentiation (2019) (2)
Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas (2020) (2)
TMOD-02. CHARACTERIZATION OF THE TUMOR IMMUNE MICROENVIRONMENT IN A PEDIATRIC HIGH GRADE GLIOMA MOUSE MODEL HARBORING THE H3.3-G34R MUTATION (2019) (2)
PDTM-20. THE HISTONE MUTATION H3.3-G34R ENCOUNTERED IN PEDIATRIC HIGH GRADE GLIOMA MODIFIES THE TUMOR IMMUNE MICROENVIRONMENT RENDERING IT MORE PERMISSIVE FOR IMMUNE MEDIATED THERAPIES (2019) (2)
269. Stimulation of the Immune System Using Gene Therapy Is an Effective Approach for Treating Brain Tumors in Mouse and Rat Models (2005) (2)
P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells (2022) (2)
CSIG-39. Fyn, AN ONCOGENE THAT REDUCES GLIOBLASTOMA SURVIVAL YET SENSITIZES TO CHEMO-RADIOTHERAPY (2017) (2)
CSIG-11. ONCOSTREAMS: NOVEL STRUCTURES THAT SPECIFY GLIOMAS’ SELF-ORGANIZATION, ARE ANATOMICALLY DISCRETE, FUNCTIONALLY UNIQUE, AND MOLECULARLY DISTINCT (2017) (2)
[Effect of monoamines on ACTH secretion by dispersed perfused cells from the adenohypophysis of barcino chico duck (Anas flavirostris)]. (1986) (2)
Corticotropin-releasing (CRH) activity of thymic peptides on CRH-insensitive corticotropic tumor cells. (1993) (2)
Gene Therapy From Theoretical Potential to Clinical Implementation (2013) (2)
Antibodies to neuropeptide precursors expressed as fusion proteins in E. coli. Their use to examine neuropeptide biosynthetic pathways, intracellular trafficking and physiological activities. (1992) (2)
RAPID, SENSITIVE DETECTION OF MYCOPLASMA SPECIES CONTAMINATION USING A HYBRIDISATION PROTECTION ASSAY SYSTEM MEMBRANE ADSORBERS AS A TOOL FOR RAPID PURIFICATION OF GENE THERAPY PRODUCTS (2004) (2)
459. Immune System Regulation of Transgene Expression in the Brain 1: Systemically Activated Immune Responses Silence Adenoviral Vector-Encoded Transgene Expression in the Brain Through Both Non-Cytolytic, and Cytotoxic Mechanisms (2004) (2)
Cell Type Specific and Inducible Transgenesis in the Anterior Pituitary Gland (2001) (1)
IB-01GLIOMA-DERIVED GALECTIN-1 IS A POTENT SUPPRESSOR OF NK IMMUNOSURVEILLANCE. (2014) (1)
Immunological synapses do not restrict secretion of interferon {gamma} during antigen-specific lysis of target cells by CD-8+ cytotoxic T lymphocytes (2011) (1)
Abstract 5101: Characterization of a mouse model using the Sleeping Beauty transposon method to study diffuse intrinsic pontine glioma (DIPG) (2018) (1)
The Proto-Oncogene Fyn Inhibits the Anti-Glioblastoma Immune Response (2019) (1)
Abstract CT105: First in human phase I trial of adenoviral vectors expressing Flt3L and HSV1-TK to treat newly diagnosed high-grade glioma by reprogramming the brain immune system (2020) (1)
GENE-34. MOUSE MODEL OF DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING Acvr1 G328V (2018) (1)
Corticotrophin-releasing hormone-like immunoreactive neurones in the rat cerebral cortex (1992) (1)
Co-localisation of autoimmune antibodies specific for double stranded DNA with procorticotrophin-releasing hormone within the nucleus of stably transfected CHO-K1 cells (1995) (1)
Contents Vol. 70, 1999 (1999) (1)
Molecular Neurosurgery in the Pituitary Gland (2005) (1)
PM-07LOSS OF ATRX DECREASES SURVIVAL AND IMPROVES RESPONSE TO DNA DAMAGING AGENTS IN A NOVEL MOUSE MODEL OF GLIOBLASTOMA (2014) (1)
Intracellular Retention of the Corticotrophin-releasing Hormone (CRH) Precursor Within COS-7 Cells (1998) (1)
Therapeutic reversal of prenatal pontine ID1 signaling in DIPG (2021) (1)
Chronic Rejection Hyporesponsiveness , But Does Not Prevent Survival and Donor-Specific Results in Long-Term Heart Allograft Interactions by Gene Transfer of CD 40 Ig Prolonged Blockade of CD 40-CD 40 Ligand Löwenstein and Ignacio Anegon (2002) (1)
The IDH-Tau-EGFR triad defines diffuse glioma pathology by controlling mesenchymal differentiation and neo-vascular fitness (2019) (1)
Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy (2021) (1)
GENE-35. IDH1-R132H INDUCES AN EPIGENETIC REPROGRAMMING IN GLIOMA IMPACTING MEDIAN SURVIVAL, DNA-DAMAGE RESPONSE AND RADIO-SENSITIVITY (2018) (1)
Spatiotemporal analysis of glioma heterogeneity reveals Col1A1 as an actionable target to disrupt tumor mesenchymal differentiation, invasion and malignancy (2020) (1)
Production and release of corticotropin releasing hormone (CRH) from AtT-20 cells stably transfected with the human CRH gene. (1990) (1)
RDNA-03. AUTOPHAGY AS A NOVEL THERAPEUTIC TARGET IN MUTANT IDH1 GLIOMAS (2019) (1)
Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models. (2020) (1)
DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE (2021) (1)
Abstract 1909: B cells present tumor antigen and mediate anti-tumor immunity induced by a combined immune-stimulatory/conditional cytotoxic therapy for glioblastoma (2010) (1)
946. CD8+ T Cells Are Partially Mediate the Immune-Mediated Silencing of Adenoviral Vector-Encoded Transgene Expression in the Rat Brain (2005) (1)
GENT-10. CHARACTERIZING AND TARGETING PDGFRA ALTERATIONS IN PEDIATRIC HIGH-GRADE GLIOMA (2016) (1)
Zinc Finger MYND-Type Containing 8 (ZMYND8) is epigenetically regulated in mutant Isocitrate Dehydrogenase 1 (IDH1) glioma to promote radioresistance (2022) (1)
Editorial [Hot Topic: Gene Therapy for Cancer (Guest Editor: Maria G. Castro)] (2005) (1)
Gene therapy for neurological disorders (2006) (1)
TMIC-58. THE CELLULAR AND MOLECULAR BASIS FOR MESENCHYMAL TRANSFORMATION IN GLIOMAS (2019) (1)
1019. Immune System Regulation of Transgene Expression in the Brain 2: Differential Increase of mRNAs Encoding for Interferon-Regulated, Chemokine, and T-Cell Genes during Either Innate Acute or Chronic Systemic Adaptive Immune Responses to First Generation Adenoviral Vectors (2004) (1)
Effects of Adenovirus-Driven Proteinase Overexpression on the Patterns of Diabetic Corneal Markers in Organ-Cultured Normal Human Corneas (2009) (1)
Abstract 1700: Novel microfluidic blood-brain niche to study breast cancer metastasis to the brain (2016) (1)
Viral gene therapy for central nervous system diseases (2016) (1)
Abstract 4795: Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo (2010) (1)
CSIG-08. DYNAMICS OF GLIOMA GROWTH: SELF-ORGANIZATION GUIDES THE PATTERNING OF THE EXTRACELLULAR MATRIX AND REGULATES TUMOR PROGRESSION (2018) (1)
Abstract 995: Loss of ATRX decreases survival and improves response to DNA damaging agents in a novel mouse model of glioblastoma (2014) (1)
Adenovirus-mediated Expression of GAD65 into the Trigeminal Ganglion Produces Long-lasting Analgesia: 883 (2008) (1)
C-met Overexpression Restores Normal Wound Healing and Marker Patterns in Organ-cultured Human Diabetic Corneas (2009) (1)
Immunotherapies for Brain Cancer: From Preclinical Models to Human Trials (2014) (1)
Oncostreams: Self-organization and dynamics determine spatial heterogeneity and malignant behavior in gliomas (2020) (1)
790. Regulatable Transgene Expression from Gutless Adenoviral Vectors (2004) (1)
Effect of various peptides on the release of ACTH, using perfused, dispersed duck pituitary cells (1984) (1)
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors (2022) (1)
Nuclear localisation of corticotrophin releasing hormone (CRH) in transfected CHO-K1 cells. (1993) (1)
Glioblastoma multiforme (GBM): a comparative histological analysis of gliomas in mice, rats, dogs and humans (2006) (1)
DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG (2020) (0)
Comparison of intratumoral loading of Flt3L/TK-recruited dendritic cells and systemic vaccination with tumor-lysate loaded dendritic cells in the stringent syngeneic CNS1 rat glioma model: Effect of temozolomide on anti-glioma immunity. (2010) (0)
CNSC-14. ROLE OF A COLLAGEN RECEPTOR, LAIR-1, IN GLIOMA CELLS: A POTENTIAL THERAPEUTIC TARGET (2022) (0)
Plasmacytoid dendritic cells mediate glioma regression and immunological memory in a syngeneic rat model. (2008) (0)
Therapeutic implications of perivascular invasion in the context of high-density brain microvascular networks: A study on recursive pattern formation in malignant glioma. (2014) (0)
In vivo tumor antigen phagocytosis and trafficking by macrophages and pDCs infiltrating intracranial glioblastomas (GBM) in rats treated with adenoviruses (Ads) expressing TK and Flt3L (2008) (0)
Evaluation of proapototic transgenes to use in combination with Flt3L in an immune‐stimulatory gene therapy approach for Glioblastoma multiforme (GBM) (2008) (0)
273. Effects of Pre-Existing Immunity on Gene Therapy Mediated by First Generation or High Capacity Adenoviral Vectors Expressing Flt3L in a Syngeneic Glioma Model (2005) (0)
High-Capacity Adenovirus Vector-Mediated Anti-Glioma Gene Therapy in the Presence of Systemic Antiadenovirus Immunity (2008) (0)
Evolutionary basis of a new approach for the treatment of malignant brain tumors: from mice to humans (2018) (0)
ANGI-10. GENETIC DOWN REGULATION OF CXCR4 IN GLIOMA CELLS REDUCES INVASION, REDUCES TUMOR PROGRESSION, AND INCREASES SENSITIVITY TO RADIATION (2016) (0)
Abstract 3414: Identifying dysregulated lncRNAs and miRNAs in low grade glioma: Uncovering signaling pathways and novel therapeutic targets (2019) (0)
Murine brain tumor microenvironment immunophenotyping using mass cytometry (2022) (0)
Abstract 2476: Spatiotemporal analyses of preclinical glioma models reveal ‘oncostreams’ as dynamic fascicles regulating tumor mesenchymal transformation, invasion, and malignancy (2022) (0)
Erratum: Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas (Molecular Therapy (2001) vol. 4 (593-602)) (2002) (0)
982. Adaptive Immune System Down-Regulates Transgene Expression from Adenovirally Infected Neurons in the Brain In Vivo (2006) (0)
Immune cells involved in tumor regression in syngeneic rat and mouse models of glioma (2005) (0)
Effect of Caveolin-1 upon Stat3-ptyr705 levels in breast and lung carcinoma cells. (2019) (0)
TMIC-62. INHIBITION OF TUMOR-ASSOCIATED COL1A1 MATRIX ARRESTS GLIOMA MESENCHYMAL TRANSFORMATION AND REPROGRAMS THE TUMOR MICROENVIRONMENT (2022) (0)
Gene Therapy for High Grade Glioma: The Clinical Experience (2022) (0)
Neurotropic Viral Infections: Viral gene therapy for central nervous system diseases (2008) (0)
Abstract 457: Depletion of glioma infiltrating myeloid derived suppressor cells promotes anti-tumor T cell responses (2015) (0)
Gene Therapy Approaches Using Reproducible and Fully Penetrant Lentivirus-Mediated Endogenous Glioma Models (2015) (0)
Cancer Therapy : Preclinical Engineering the Brain Tumor Microenvironment Enhances the Efficacy of Dendritic Cell Vaccination : Implications for Clinical Trial Design (2011) (0)
Abstract 4145: Brain-derived endothelial cells stimulate migration of different human, mouse, and rat glioma cell lines in vivo and in vitro (2015) (0)
Radiation-reprogrammed glioma stem cells generate vascular-like cells to build a trophic niche driving tumor recurrence (2021) (0)
Subject Index Vol. 70, 1999 (1999) (0)
CSIG-07. COMPARATIVE RNA-SEQ ANALYSIS OF GLIOMAS OF DIFFERENT MALIGNANCY IDENTIFIES FYN AS A NOVEL REGULATOR OF GBM AGGRESSIVENESS (2018) (0)
GENT-53. SELF-ORGANIZATION OF GLIOMAS: GENETIC RODENT MODELS, GENOMIC NETWORKS, AND MATHEMATICAL MODELING (2016) (0)
REVEALS POTENTIAL OF THERAPY-DRIVEN TUMOR EVOLUTION GENT-53. SELF-ORGANIZATION OF GLIOMAS: GENETIC RODENT MODELS, GENOMIC NETWORKS, AND MATHEMATICAL MODELING - PRECLINICAL STUDIES COMBINING TOCA 511 AND 5-FLUOROCYTOSINE WITH CHECKPOINT INHIBITORS SIGNIFICANTLY REDUCED TUMOR BURDEN IN A MOUSE MODEL O (2016) (0)
Formation of in vivo immunological synapses (IS) between CTLs and virally infected astrocytes leads astrocyte to polarization mediated by the activation of a Rho‐GTPase signaling pathway. (2008) (0)
Impact of epigenetic reprogramming on antitumor immune responses in glioma (2023) (0)
424. Myd88/TLR Signaling Is Required for Immunotherapy-Mediated Glioblastoma Regression (2006) (0)
IL-10 and TGF- are both needed to down-modulate inflammation induced by FasL from first generation adenovirus vectors in the brain, while either IL-10 and TGF- can inhibit FasL-dependent inflammation in muscle (2001) (0)
Transfection of Uninjured Organ-Cultured Human Corneas by Gfp-Expressing Adenovirus and Adeno-Associated Viruses (2007) (0)
Adenovirus-Mediated Gene Transfer of Transforming Growth Factor- (cid:1) 3 , but Not Transforming Growth Factor- (cid:1) 1 , Inhibits Constrictive Remodeling and Reduces Luminal Loss After Coronary Angioplasty (2003) (0)
Abstract 4798: Cytotoxic T cells kill tumor cells in a contact and antigen-dependent manner, but the interaction affects neighboring, non-target cells via interferon gamma secretion (2010) (0)
POSTER PRESENTATIONS: P-23: REPAIR OF SPINAL CORD INJURY (SCI) USING BONE MARROW STROMAL CELL TRANSFECTED WITH ADENOVIRAL VECTOR EXPRESSING GLIAL DERIVED NEUROTROPHIC FACTOR (GDNF) IN A RAT SCI MODEL (2011) (0)
Abstract 187: Absence of S100A9 confers survival advantage in an aggressive de novo mouse model of glioblastoma multiforme (2014) (0)
ATRX Loss in Glioma Results in Epigenetic Dysregulation of Cell Cycle Phase Transition (2021) (0)
The cellular biology underlying immune responses against brain tumors: the in vivo formation and function of immunological synapses, and the polarized secretion of effector cytokines (2008) (0)
Adenoviral mediated suicide gene therapy using the bacterial enzyme Carboxypeptidase G2 (2002) (0)
Combined gene therapy for the treatment of gliomas macroscopic. (2005) (0)
Inhibition of STAT3 using shRNA inhibits Thymidine Kinase (TK) mediated glioma cell death in vitro and abrogates Flt3L and TK dependent tumor regression in vivo. (2008) (0)
Depletion of CD25+ T cells inhibits CD8+ T cells clonal expansion and glioblastoma multiforme regression. (2008) (0)
IMMU-26. TLR7 ACTIVATION IS ESSENTIAL FOR NK CELLS TO ELIMINATE GLIOMA TUMORS (2017) (0)
Abstract 1266: Mutant IDH1 alters epigenetic regulation to promote stemness in low grade glioma: Deciphering signaling pathways altered by mIDH1 inhibition (2020) (0)
Abstract 1322: Comparison of brain extracellular matrices in a blood brain barrier organ on a chip model (2023) (0)
De Novo Purine Synthesis Is a Targetable Vulnerability That Confers Radiation Resistance and Inferior Patient Survival in IDH-Wild Type Diffuse Glioma (2019) (0)
Interplay between ATRXand IDH1 mutations governs innate immune responses in diffuse gliomas (2023) (0)
11 Evolutionary Origins of the Brain's Immune Privilege. Implications for Novel Therapeutic Approaches: Gene Therapy (2008) (0)
HG-03A NOVEL MOUSE MODEL OF YOUNG ADULT GLIOBLASTOMA: IN VIVO EXPRESSION OF MUTATED IDH1 (R132H) GENE USING THE SLEEPING BEAUTY TRANSPOSASE SYSTEM (2015) (0)
Immune Responses to Viral Vectors Injected Systemically or into the CNS (2007) (0)
TMIC-15MYELOID DERIVED SUPPRESSOR CELLS' TRAFFICKING INTO GBM IS REGULATED BY CXCR2 SIGNALING. (2015) (0)
Abstract 3910: Analysis of metastatic potential by breast cancer type through a microfluidic blood-brain niche (2017) (0)
IMPS-01Gr-1+/CD11b+ MYELOID CELLS ARE REQUIRED FOR NATURAL KILLER CELL-MEDIATED ERADICATION OF GALECTIN-1-DEFICIENT GLIOMA. (2015) (0)
IFN-{gamma} secretion at effector immunological synapses (IS) in vivo (2008) (0)
TAMI-52. G-CSF SECRETED BY EPIGENETICALLY REPROGRAMMED MUTANT IDH1 GLIOMA STEM CELLS, REVERSES THE MYELOID CELLS’-MEDIATED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT (2020) (0)
TMOD-05MODELING ACVR1 AND HIST1H3B MUTATIONS IN DIFFUSE INTRINSIC PONTINE GLIOMA IN VIVO USING THE SLEEPING BEAUTY SYSTEM (2015) (0)
EPCT-07. ID1 IS A KEY TRANSCRIPTIONAL REGULATOR OF DIPG INVASION AND IS TARGETABLE WITH CANNABIDIOL (2021) (0)
TMIC-62. FYN, AN EFFECTOR OF ONCOGENIC RECEPTOR TYROSINE KINASES SIGNALING IN GLIOBLASTOMA, INHIBITS ANTI-GLIOMA IMMUNE RESPONSES: IMPLICATIONS FOR IMMUNOTHERAPY (2019) (0)
Radiation-induced reprogramming drives glioma vascular transdifferentiation and tumor recurrence (2021) (0)
HGG-08. ATRX LOSS IN PEDIATRIC GBM RESULTS IN EPIGENETIC DYSREGULATION OF G2/M CHECKPOINT MAINTENANCE AND SENSITIVITY TO ATM INHIBITION (2019) (0)
Abstract 3195: STAT3 inhibition using shRNA inhibits GBM proliferation, cell migration, anchorage-independent growth of mouse, rat, and human stem-like cells in vitro; and it induces long term survival and anti-GBM immunity in vivo (2015) (0)
AI-04MECHANISMS OF GLIOMA FORMATION: PERIVASCULAR GLIOMA INVASION IS A VEGF-INDEPENDENT MECHANISM OF TUMOR VASCULARIZATION (2014) (0)
ANGI-11. DIRECT GLIOMA BLOOD VESSEL DISRUPTION IMPROVES IMMUNE THERAPY BUT WORSENS ANTI-VEGF THERAPY (2017) (0)
Cell type specific and inducible transient transgenics in the anterior pituitary gland (2001) (0)
IFN-γ secretion is polarized at effector immunological synapses (IS) in vivo. (87.52) (2007) (0)
CBIO-03. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION (2020) (0)
GENE-17. GENERATION OF A MOUSE MODEL OF DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING ACVR1 G328V AND H3.1 K27M MUTATIONS (2017) (0)
Abstract 3033: Generation of a mouse model of young adult glioblatoma: In vivo expression of mutated IDH1-R132H gene using the sleeping beauty transposase system (2015) (0)
IMMU-58. IDH1 MUTATION REGULATES MYELOID CELLS MEDIATED IMMUNOSUPPRESSION IN GLIOMA (2017) (0)
147. Effective Gene Transfer to Human Glioma Cells Using High Capacity Adenoviral Vectors: Human Glioma Cells Express Substantial Levels of CAR and Integrin Adenoviral Co-Receptors (2006) (0)
TMIC-19. H+ EXTRUSION PROTEIN NA/H EXCHANGER IN METABOLIC POLARIZATION OF GLIOMA-ASSOCIATED MICROGLIA/MACROPHAGES AND TUMOR IMMUNITY (2019) (0)
Abstract 3645: Glioma-derived factors induce the expansion of myeloid derived suppressor cells which mediate immune suppression and tumor progression (2011) (0)
The Endothelium as a target for gene therapy: brain tumours, neurodegenerative disorders and cardiovascular disease (2001) (0)
Nuclear and cytoplasmic localisation of procorticotrophin releasing hormone in transfected CHO-K1 cells. (1994) (0)
Gene therapy for neurological diseases: quo vadis? Achievements and expectations of, and challenges for, the brave new technology (2020) (0)
HMGB1 Is Released into the Supernatant of GL26, LLc1, GL261, and B16-F10 Tumor Cell Lines in Response to Treatment with Ad-TK (+GCV), Irradiation, or Temozolomide (2009) (0)
Diabetic Corneal Gene Therapy With Adenoviral Vectors: Overexpression of Proteinases and C-Met in Human Organ-Cultured Corneas (2008) (0)
Abstract 3950: Spatiotemporal analysis of gliomas: Dynamics of mesenchymal multicellular structures as novel target for tumor treatment (2020) (0)
TMIC-14DEPLETION OF GLIOMA INFILTRATING MYELOID DERIVED SUPPRESSOR CELLS PROMOTES ANTI-TUMOR T CELL RESPONSES. (2015) (0)
Ad.Flt3L/Ad.TK (+GCV) gene therapy induces intracranial glioma (GBM) regression and long term immunological memory which inhibits GBM growth in the periphery in a syngeneic, rat GBM model (2008) (0)
An anti-viral immune response clears virally infected neurons from the mouse brain through cytotoxic mechanisms involving IFN-{gamma}, perforin, and TNF{alpha}. (2008) (0)
Abstract 3804: CPA-7, an inhibitor of STAT3, is a potent tumoricidal agent in peripheral tumor models and is impermeable to the CNS (2014) (0)
Target APC polarization at immunological synapses (IS) in vivo: infected astrocytes polarize towards CTL cells during the brain antiviral immune response. (91.13) (2007) (0)
Cancer Biology and Signal Transduction Blockade of mTOR Signaling via Rapamycin Combined with ImmunotherapyAugmentsAntigliomaCytotoxicandMemory T-Cell Functions (2014) (0)
Use of gene transfer to study post-translational modifications of neuropeptides in cell lines. (1994) (0)
Abstract 869: Molecular characterization of a pediatric high-grade glioma (pHGG) mouse model harboring the H3.3 G34R mutation (2019) (0)
Adenovirus-Mediated CTLA4Ig Expression and Systemic Mechanisms After Tolerance to Cardiac Allografts Via Local (2013) (0)
Pdct-03. Clinically Integrated Sequencing In The Management Of Children With High-Risk Brain Tumors (2016) (0)
Neuropeptide gene transfer into neuronal and glial cell lines. (1994) (0)
Editorial: Targeting Neuroinflammation in Central Nervous System Disorders: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments (2021) (0)
Therapeutic efficacy of an immune stimulatory gene therapy strategy in a mouse model of high grade brainstem glioma (2019) (0)
IMMU-63. IDH1 MUTATION REGULATE MYELOID CELLS PLASTICITY MEDIATING ANTI-GLIOMA IMMUNOTHERAPY (2018) (0)
PTPS-15ATRX LOSS PROMOTES TUMOR GROWTH AND IMPAIRS NON-HOMOLOGOUS END JOINING DNA REPAIR IN GLIOMA (2015) (0)
Blockade of mTOR Signaling via Rapamycin Combined with ImmunotherapyAugmentsAntigliomaCytotoxicandMemory (2014) (0)
Gene Therapy for Malignant Brain Tumors: from Experimental to Clinical Neuro-oncology (2011) (0)
Microtubule targeting agents: mechanisms of action and classification Microtubules are dynamic tubular polymers of α- and β-tubulin which provide structural integrity, promote migration, transport of molecules, vesicles and organelles and play essential roles during cell division by forming the mito (2016) (0)
Abstract 452: Monocytic Gr-1+/CD11b+ myeloid cells are necessary for natural killer cells to eradicate glioma and are inhibited by tumor-derived galectin-1 (2015) (0)
Biosynthesis and nuclear translocation of the proneuropeptide procorticotrophin-releasing hormone (proCRH) (1994) (0)
TMOD-02BLOCKING CXCR4 INCREASES SURVIVAL IN A MOUSE MODEL OF NEURAL STEM CELLS-DERIVED GLIOBLASTOMA BY BLOCKING AN AUTOCRINE POSITIVE FEEDBACK LOOP REGULATING APOPTOSIS AND CELL CYCLE PROGRESSION VIA Rb1 AND cdk4/cdk6/CyclinD1 (2015) (0)
Microenvironment and Immunology Natural Killer Cells Eradicate Galectin-1 – De fi cient Glioma in the Absence of Adaptive Immunity (2014) (0)
Abstract 1085: Glioma-infiltrating myeloid derived suppressor cells inhibit anti-tumor T cell responses (2014) (0)
Adenoviral-mediated gene transfer into the canine brain in vivo. Commentary (2007) (0)
Spatial organization of glioma collective motion (2020) (0)
Control of Proteolysis in Cell Culture (1999) (0)
ME-10TUMOR MICROENVIRONMENT INFILTRATING MYELOID DERIVED SUPPRESSOR CELLS INHIBIT ANTI-TUMOR T CELL RESPONSES (2014) (0)
Glioma trials and viral tribulations: can anything be concluded from non-controlled trials? (2014) (0)
IMG-12. CHARACTERISATION OF MODELS OF H3F3A_G34R/V MUTANT PAEDIATRIC GLIOBLASTOMA IN VIVO USING MAGNETIC RESONANCE IMAGING (2020) (0)
IMMU-61. INHIBITION OF MUTANT IDH1 WITH AGI-5198 ENHANCES THE EFFICACY OF RADIOTHERAPY ELICITING IMMUNOLOGICAL MEMORY AND IMPROVING OVERALL SURVIVAL (2018) (0)
Abstract 3103: Analysis of breast cancer lines and PDXs using a blood brain niche (µm-BBN) microfluidic device and algorithms to aid diagnosis of brain metastatic potential (2018) (0)
LGG-17. DECREASED FUNCTION OF ISOPRENYLCYSTEINE CARBOXYLMETHYLTRANSFERASE RESULTS IN INCREASED SENSITIVITY TO CHEMORADIATION IN OLIGODENDROGLIOMA (2019) (0)
851. Molecular Determination of High-Capacity Helper Dependent Adenoviral Vector Genomes In Vitro and In Vivo (2006) (0)
Abstract 3009: ATRX validated as tumor suppressor in a novel mouse model of pediatric and young adult GBM (2015) (0)
HG-02ATRX LOSS PROMOTES TUMOR GROWTH AND IMPAIRS GENETIC STABILITY IN GLIOBLASTOMA (2015) (0)
An anti‐viral immune response clears virally infected neurons from the mouse brain through cytotoxic mechanisms involving IFN‐γ, perforin, and TNFα. (2008) (0)
Generation of 3D ex vivo mouse- and patient-derived glioma explant slice model for integration of confocal time-lapse imaging and spatial analysis (2023) (0)
The Brain as a Target for Gene Therapy (2007) (0)
GENT-06. IN VIVO EXPRESSION OF MUTATED IDH1 (R132H) GENE IN A MOUSE MODEL OF YOUNG ADULT GLIOBLASTOMA HAS IMPACT IN MEDIAN SURVIVAL, DNA-REPAIR PATHWAYS, AUTOPHAGY AND OLIGODENDROCYTE DIFFERENTIATION (2016) (0)
IFN-{gamma} secretion is polarized at effector immunological synapses (IS) in vivo. (2007) (0)
Progress in gene therapy for neurological (2013) (0)
Abstract PR005: The dynamic tumor microenvironment: Oncostreams are self-organizing structures that modulate glioma progression and treatment (2021) (0)
621. Immunological Memory in a Syngeneic Model of Recurrent and Multifocal Glioblastoma (2006) (0)
TMIC-35. IDH1 MUTATION IN GLIOMA REPROGRAMS EARLY MYELOID DIFFERENTIATION IN THE BONE MARROW (BM) TO PRODUCE NON-IMUNESUPPRESSIVE NEUTROPHILS (2019) (0)
ANGI-16IN VIVO AND IN VITRO STUDIES SHOW THAT BRAIN DERIVED ENDOTHELIAL CELLS STIMULATE MIGRATION OF HUMAN, MOUSE AND RAT GLIOMA CELLS (2015) (0)
Inducible suicide gene expression from first generation adenoviral vectors expressing Carboxypeptidase G2 in a secreted and membrane bound form (2000) (0)
Gene transfer into cultured bovine ciliary epithelial cells using adenovirus vectors. (1996) (0)
661. Immune System Regulation of Transgene Expression in the Brain 3: Effects of the Immune Response on Transgene Expression from HIV-Derived Lentiviral Vectors Injected into the Rat Striatum (2004) (0)
A recombinant adenovirus vector expressing Transforming Growth Factor-β3 gives rise to high level expression of TGF-β3 in cultured vascular smooth muscle cells: Potential gene therapy for restenosis (1999) (0)
TAMI-79. THERAPEUTIC REVERSAL OF PRENATAL PONTINE ID1 SIGNALING IN DIPG (2021) (0)
999. Mature Effector Immunological Synapses Forming SMAC Mediate Clearance of Virally Infected Astrocytes from the Brain In Vivo (2006) (0)
143. Regulated, High Capacity Adenoviral Vectors Mediated Long-Term Gene Expression in the Brain Even in the Presence of a Peripheral Immune Response to Adenovirus (2005) (0)
Improved factor VIII variants for gene therapy (0)
Correction to: CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway (2021) (0)
apoptosis sensitize anterior pituitary gland to (2005) (0)
MPTH-18STREAMS, VORTICES, AND NEUROSPHERES: IN VIVO NON-RANDOM LARGE SCALE SELF-ORGANIZATION OF GLIOBLASTOMA MULTIFORME AND THE ROLE OF NOVEL HISTOPATHOLOGICAL STRUCTURES (2015) (0)
Draft 1 Effect of Caveolin-1 upon Stat 3-ptyr 705 levels in breast and lung carcinoma cells (2019) (0)
GENE-32. SYNTHETIC LETHAL INTERACTIONS WITH IDH1R132H IN GLIOMA STEM-LIKE CELLS (2019) (0)
Transient Transgenesis in The Endocrine System: Viral Vectors for Gene Delivery (2001) (0)
430. Immune System Regulation of Transgene Expression from High-Capacity Gutless Adenoviral Vectors in the Mouse Brain: Very Long Term Expression Following Pre-Immunization (2005) (0)
The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors. (2016) (0)
DIPG-38. ID1 EXPRESSION CORRELATES WITH H3F3A K27M MUTATION AND EXTRA-PONTINE INVASION IN DIPG (2018) (0)
Prediction of protein antigenic sites in human corticotrophin-releasing hormone precursor. (1993) (0)
Abstract 3825: Synergistic antitumor effect of chemotherapy and immunotherapy in syngeneic brain tumor models in mice (2010) (0)
Systemic Flt3L and intratumoral HSV1‐TK treatment eradicates intracranial GBM in a syngeneic model (2008) (0)
GENE-58. EPIGENETIC REPROGRAMMING IN MUTANT IDH1 GLIOMA IMPACTS MEDIAN SURVIVAL, ENHANCES DNA DAMAGE RESPONSE AND CONFERS RADIO-RESISTANCE (2017) (0)
Immune responses to transgenes encoded within gutless adenovirus vectors (HC‐Ads) delivered into the brain (2008) (0)
Lentiviral-Induced High-Grade Gliomas in Rats: The Effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H (2014) (0)
Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy (2018) (0)
TAMI-29. MULTIFACTORIAL UPREGULATION OF ID1 DRIVES DIPG INVASIVENESS AND IS THERAPEUTICALLY TARGETABLE (2020) (0)
CELL TYPE SPECIFIC EXPRESSION IN THE PITUITARY: PHYSIOLOGY AND CANCER TREATMENT (1999) (0)
745. CD4-T Cell Responses Mediated by IFN|[gamma]| and Perforin Eliminate Adenoviral-Mediated Transgene Expression from the CNS of Mice by Cytolytic and Non-Cytolytic Mechanisms (2005) (0)
Treatment of experimental intracranial glioblastoma (GBM) with adenoviruses expressing TK and Flt3L induce intratumoral infiltration of phagocytic immature plasmacytoid dendritic cells (2008) (0)
EXTH-47. THERAPEUTIC REVERSAL OF PRENATAL PONTINE ID1 SIGNALING IN DIPG (2019) (0)
TMIC-18. ROLE OF DISCOIDIN DOMAIN RECEPTORS (DDR1/DDR2) IN SENSITIZATION OF GLIOMAS TOWARDS RADIOTHERAPY (2022) (0)
IMMU-03. SUPPRESSION OF ONCOMETABOLITE 2-HYDROXYGLUTRATE PRODUCED BY MUTANT IDH1 GLIOMA WITH AGI-5198 ENHANCES THE EFFICACY OF RADIOTHERAPY AND IMMUNE CHECKPOINT BLOCKADE ELICITING IMMUNOLOGICAL MEMORY (2019) (0)
Immune-mediated brain tumor regression requires HMGB1 release and subsequent TLR2 activation on tumor infiltrating dendritic cells (2008) (0)
Overcoming brain immune privilege with Flt3L and TK treatment in a recurrent rat glioma model (2008) (0)
Hand-arm vibration in the pass and reception on basketball (2021) (0)
IFN‐γ secretion at effector immunological synapses (IS) in vivo (2008) (0)
CBIO-10. REVERSIBILITY OF GLIOMA STEM CELLS’ SPHERE FORMATION EXPLAINS THEIR IN VITRO BEHAVIOR AND IN VIVO TUMORIGENESIS POTENTIAL (2016) (0)
Adenoviral-mediated delivery of a mutated form of IL-13 (IL13.E13.K) fused to Pseudomonas exotoxin A exerts increased efficacy and reduced toxicity when compared to Cintredekin Besudotox in intracranial human glioma xenografts. (2008) (0)
First in Human Phase I Trial of Dual Vector (HSV1-TK, Flt3L) Immunotherapy For The Treatment of Newly Diagnosed High-Grade Glioma: Initial Results (2019) (0)
Adenovirus-Mediated HSV-tk Gene Therapy for Malignant Glioma: Clinical Experience (2016) (0)
Editorial: Physical Activity: An Optimizer of the Neurophysiological System? (2021) (0)
Efficiency of particle search methods in smoothed particle hydrodynamics: a comparative study (part I) (2021) (0)
TMOD-08. ELUCIDATING EPIGENETIC MECHANISMS IN DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING ACVR1 G328V AND H3.1 K27M (2019) (0)
Intracellular compartmentalisation of procorticotrophin releasing hormone. (1993) (0)
TMOD-11. USING THE SLEEPING BEAUTY TRANSPOSASE SYSTEM TO GENERATE MOUSE MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING ACVR1 AND H3K27M MUTATIONS (2016) (0)
GENE-17. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF THE G2/M CHECKPOINT AND SENSITIVITY TO ATM INHIBITION (2019) (0)
Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF-κB Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model (2012) (0)
Abstract 467: Circulating DNA released from brain tumors in response to conditional cytotoxic/immune stimulatory gene therapy induces activation of TLR9 on pDCs, leading to antitumor immunity (2011) (0)

This paper list is powered by the following services:

Other Resources About Maria G. Castro

en.wikipedia.org

What Schools Are Affiliated With Maria G. Castro?

Maria G. Castro is affiliated with the following schools:

Maria G. Castro's Academic­Influence.com Rankings